AcquisitionsMar 29, 2026, 08:10 PM
Gilead Sciences to Acquire Arcellx for $115 per Share Plus Contingent Value Right
AI Summary
Gilead Sciences has entered into a definitive agreement to acquire Arcellx, Inc. through a tender offer. The offer includes $115.00 per share in cash and one contingent value right (CVR) representing the right to receive $5.00 upon achievement of a specified milestone, potentially expanding Gilead's oncology pipeline.
Key Highlights
- Gilead will acquire all outstanding shares of Arcellx common stock.
- The offer consists of $115.00 per share in cash plus one CVR.
- The CVR entitles holders to a contingent payment of $5.00 upon milestone achievement.
- The tender offer will remain open for a minimum of 20 business days.